Optimal glucocorticoid replacement in adrenal insufficiency.

Area of Science:

• Endocrinology
• Internal Medicine
• Rare Diseases

Background:

• Adrenal insufficiency (AI), including primary AI, secondary AI, and congenital adrenal hyperplasia, is a group of rare diseases.
• While glucocorticoid therapy has been lifesaving for over 60 years, its long-term effects, morbidity, and mortality remain poorly understood.
• Recent studies indicate reduced quality of life, adverse metabolic profiles, and increased mortality in AI patients, potentially due to unphysiological glucocorticoid replacement.

Purpose of the Study:

• To review the evidence on the inadequacy of conventional glucocorticoid replacement therapy in adrenal insufficiency.
• To discuss recent advancements in treatment strategies aimed at improving patient outcomes.
• To emphasize developments in primary adrenal insufficiency management.

Main Methods:

• Systematic review of cohort and registry studies.
• Analysis of evidence regarding treatment effects, morbidity, and mortality in adrenal insufficiency.
• Focus on developments in glucocorticoid replacement therapy.

Main Results:

• Conventional glucocorticoid replacement is often unphysiological, leading to negative health consequences.
• Patients with adrenal insufficiency experience reduced quality of life and increased mortality.
• Newer replacement strategies are being developed to better mimic normal glucocorticoid physiology.

Conclusions:

• Current glucocorticoid replacement therapy for adrenal insufficiency has significant limitations.
• There is a need for improved treatment modalities that better replicate physiological hormone secretion.
• Advancements in treatment offer potential for improved long-term outcomes in patients with adrenal insufficiency, particularly primary AI.